Gregory Mark Weinhoff

Corporate Officer/Principal chez CENTESSA PHARMACEUTICALS PLC

Profil

Dr. Gregory Mark Weinhoff is a Chief Business Officer at Centessa Pharmaceuticals Plc and a Venture Partner at Healthinvest Equity Partners.
Dr. Weinhoff was previously employed as a Chief Financial & Business Officer by Arvelle Therapeutics BV, a Chief Financial & Business Officer, Director by Arvelle Therapeutics International GmbH, a Chief Financial & Accounting Officer by Axovant Gene Therapies Ltd., a Chief Financial Officer by Axovant Sciences, Inc., a Chief Executive Officer & Director by Amicus Therapeutics, Inc., a Partner by CHL Healthcare Partners LLC, a Senior Associate by J.
H.
Whitney & Co. LLC, a Financial Analyst by Morgan Stanley & Co., Inc., an Executive Chairman by Resolvyx Pharmaceuticals, Inc., and a Senior Associate by W.G.
Shaheen & Associates Ltd. He also served on the board at Ella Health, Inc., Celula, Inc., Concerto Health Services, Inc., LuMend, Inc., PrimeraDx, Inc. and VaxInnate Corp.
He received his undergraduate degree from Harvard College, an MBA from Harvard Business School and a doctorate degree from Harvard Medical School.

Postes actifs de Gregory Mark Weinhoff

Sociétés	Poste	Début
CENTESSA PHARMACEUTICALS PLC	Corporate Officer/Principal	10/06/2024
Healthinvest Equity Partners	Private Equity Investor	-

Anciens postes connus de Gregory Mark Weinhoff

Sociétés	Poste	Fin
Arvelle Therapeutics BV	Fondateur	01/02/2021
Axovant Sciences, Inc.	Directeur Financier/CFO	30/06/2019
SIO GENE THERAPIES INC.	Directeur Financier/CFO	30/06/2019
AMICUS THERAPEUTICS, INC.	Directeur Général	07/01/2009
J.H. Whitney Capital Partners, LLC	Corporate Officer/Principal	01/01/2001